EUVIMEDEUVIMED entdecken
Multizentrische Studie

Evidence of bioprosthetic valve dysfunction during three-year follow-up following TAVR

Verena Veulemans, Jacqueline Heermann, Rik Adrichem, Salome Hecht, Philipp C Seppelt, Thijmen W Hokken, Rutger-Jan Nuis, Mohamed Abdel-Wahab, Nicolas M van Mieghem, David Leistner, Marc M Vorpahl, Tobias Zeus

Clinical Research in Cardiology · 2026

DOI: 10.1007/s00392-025-02630-7 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Research in Cardiology, 2026. Verfasst von Verena Veulemans und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich Heine University, Medical Faculty, Moorenstr. 5, 40225, Düsseldorf, Germany. vere…. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Bioprosthesis, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Transcatheter aortic valve replacement (TAVR) has increased significantly in younger patients and patients at lower surgical risk. In this retrospective multicenter study, we aimed to assess for bioprosthetic valve dysfunction (BVD) during three-year follow-up (FU) and potential differences between self-expandable (SEV) and balloon-expandable valves (BEV) under real-world conditions. METHODS: Endpoints were defined according to VARC-3 criteria, including VARC composite endpoints during three-year FU. RESULTS: A total of 1233 patients with tricuspid aortic valve stenosis, who underwent TAVR with contemporary transcatheter heart valve (THV) devices from three different tertiary care centers were included. One-fifth of the study population showed BVD at three-year FU (BVD[-]: n = 957;77.6%; BVD[+]: n = 276;22.4%). Non-structural valve deterioration (NSVD) was the most represented category (8.5%) followed by structural valve deterioration (SVD, 5.3%). BVD was more common in association with BEV as compared with SEV (60.9% vs 39.1%; p < 0.001) owing to higher rates of SVD (13.5% vs 9.5%; p = 0.028) and NSVD (17.9% vs. 13.8%; p = 0.048). Subclinical leaflet thrombosis was only documented in BEV (1.7%, p < 0.001). At three years, all-cause mortality was higher in BVD+ patients (BVD[-] vs. BVD[+]: 13.2% vs. 22.5%; HR: 1.99; 95%-CI: 1.39-2.85; p < 0.001*) but did not differ between THV platform. CONCLUSION: BVD after TAVR is common and associated with higher all-cause mortality. Despite a preponderance of BVD in association with balloon-expandable valves, mortality rates remain similar between THV platforms. CLINICAL TRIAL REGISTRATION: NCT01805739.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve ProsthesisBioprosthesisAortic Valve StenosisTranscatheter Aortic Valve ReplacementProsthesis FailureAortic ValvePostoperative ComplicationsHumansFemaleRetrospective StudiesFollow-Up StudiesMaleProsthesis DesignAged, 80 and overTime FactorsRisk FactorsTreatment OutcomeAged

Stichwörter der Autor:innen

Bioprosthetic dysfunctionTAVITAVR

Autor:innen und Institutionen

  • Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich Heine University, Medical Faculty, Moorenstr. 5, 40225, Düsseldorf, Germany. verena.veulemans@web.de.
  • Department for Cardiology, Heartcenter Siegburg, Ringstr. 49, 53721, Siegburg, Germany. verena.veulemans@web.de.
  • Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich Heine University, Medical Faculty, Moorenstr. 5, 40225, Düsseldorf, Germany.
  • Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Department for Cardiology, Heartcenter Leipzig, Strümpellstr. 39, 04289, Leipzig, Germany.
  • Department for Cardiology, Heartcenter Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany.

Zitieren

APA

Veulemans, V., Heermann, J., Adrichem, R., Hecht, S., Seppelt, P. C., Hokken, T. W., Nuis, R. J., Abdel-Wahab, M., van Mieghem, N. M., Leistner, D., Vorpahl, M. M., & Zeus, T. (2026). Evidence of bioprosthetic valve dysfunction during three-year follow-up following TAVR. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-025-02630-7

Vancouver

Veulemans V, Heermann J, Adrichem R, Hecht S, Seppelt PC, Hokken TW, et al. Evidence of bioprosthetic valve dysfunction during three-year follow-up following TAVR. Clinical Research in Cardiology. 2026. doi:10.1007/s00392-025-02630-7

BibTeX
@article{Veulemans2026,
  author = {Veulemans, Verena and Heermann, Jacqueline and Adrichem, Rik and Hecht, Salome and Seppelt, Philipp C and Hokken, Thijmen W and Nuis, Rutger-Jan and Abdel-Wahab, Mohamed and van Mieghem, Nicolas M and Leistner, David and Vorpahl, Marc M and Zeus, Tobias},
  title = {Evidence of bioprosthetic valve dysfunction during three-year follow-up following TAVR},
  journal = {Clinical Research in Cardiology},
  year = {2026},
  doi = {10.1007/s00392-025-02630-7}
}
Kostenlos starten →